← Leaderboards
Siddappa N Byrareddy
Emory University
$14,019,085
Attributed
$25,794,637
Total exposure
11
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2013–25$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,794,637 · 11
By mechanism
R01$24,746,886 · 8
R21$1,047,751 · 3
Top collaborators
- Shilpa J Buch10 shared
- Mahesh Mohan7 shared
- Howard S. Fox5 shared
- Udaykumar Ranga5 shared
- Lishomwa C Ndhlovu4 shared
- Mirko Paiardini4 shared
- Pamela J Skinner4 shared
- Eva Gizella Rakasz2 shared
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionViralMacaca MulattaChronicCellsVirusHiv InfectionsSiteMacacaViral ReservoirViral Load ResultDisease ProgressionAntiretroviral TherapyBrainPathogenesisBaseComorbidityMicrogliaPlasmaMolecularPreventSeriesAnimalsReceptor
Grant awards (38)
Cannabinoid inhibition of CNS inflammasome activation via modulation of the gut-brain axis$898,025
R01 · FY2025 · DA · contact PI
Targeting CNS reservoirs with CAR/CXCR5 T cells for the long-term remission of HIV$893,519
R01 · FY2025 · MH
Sex differences in modulating HIV/SIV reservoirs in the context of opioids$682,060
R01 · FY2025 · DA · contact PI
Targeting CNS reservoirs with CAR/CXCR5 T cells for the long-term remission of HIV$893,519
R01 · FY2024 · MH
Epigenetic mechanisms underlying cannabinoid modulation of neuroinflammation in HIV/SIV infection$692,889
R01 · FY2024 · DA
Sex differences in modulating HIV/SIV reservoirs in the context of opioids$690,750
R01 · FY2024 · DA · contact PI
Targeting CNS reservoirs with CAR/CXCR5 T cells for the long-term remission of HIV$893,519
R01 · FY2023 · MH
Epigenetic mechanisms underlying cannabinoid modulation of neuroinflammation in HIV/SIV infection$696,885
R01 · FY2023 · DA
Targeting CNS reservoirs with CAR/CXCR5 T cells for the long-term remission of HIV$929,754
R01 · FY2022 · MH
Epigenetic mechanisms underlying cannabinoid modulation of neuroinflammation in HIV/SIV infection$700,759
R01 · FY2022 · DA
Epigenetic mechanisms underlying cannabinoid modulation of neuroinflammation in HIV/SIV infection-supplement$472,498
R01 · FY2022 · DA
Epigenetic mechanisms underlying cannabinoid modulation of neuroinflammation in HIV/SIV infection$704,526
R01 · FY2021 · DA
Limiting HIV establishment and maintenace by preserving intestinal immunity$828,836
R01 · FY2020 · AI · contact PI
The brain as a SIV reservoir under suppressive cART potentiation by drugs of abuse$752,188
R01 · FY2020 · DA
Epigenetic mechanisms underlying cannabinoid modulation of neuroinflammation in HIV/SIV infection$730,433
R01 · FY2020 · DA
The combinatorial effects of Opiates and the emerging promoter-variant strains of HIV-1 subtype C on HIV neuropathogensis and latency$718,779
R01 · FY2020 · DA
Limiting HIV establishment and maintenace by preserving intestinal immunity$829,776
R01 · FY2019 · AI · contact PI
The combinatorial effects of Opiates and the emerging promoter-variant strains of HIV-1 subtype C on HIV neuropathogensis and latency$757,800
R01 · FY2019 · DA
The brain as a SIV reservoir under suppressive cART potentiation by drugs of abuse$752,188
R01 · FY2019 · DA
The combinatorial effects of Opiates and the emerging promoter-variant strains of HIV-1 subtype C on HIV neuropathogensis and latency$830,071
R01 · FY2018 · DA
Limiting HIV establishment and maintenace by preserving intestinal immunity$829,440
R01 · FY2018 · AI · contact PI
The brain as a SIV reservoir under suppressive cART potentiation by drugs of abuse$752,188
R01 · FY2018 · DA
Role of HIV Env glycosylation in mucosal transmission$681,834
R01 · FY2018 · AI · contact PI
Targeting gut-brain axis to eliminate CNS reservoirs$188,125
R21 · FY2018 · MH · contact PI
Limiting HIV establishment and maintenace by preserving intestinal immunity$847,715
R01 · FY2017 · AI · contact PI
The combinatorial effects of Opiates and the emerging promoter-variant strains of HIV-1 subtype C on HIV neuropathogensis and latency$838,842
R01 · FY2017 · DA
The brain as a SIV reservoir under suppressive cART potentiation by drugs of abuse$752,188
R01 · FY2017 · DA
Role of HIV Env glycosylation in mucosal transmission$705,487
R01 · FY2017 · AI · contact PI
Targeting gut-brain axis to eliminate CNS reservoirs$225,750
R21 · FY2017 · MH · contact PI
The brain as a SIV reservoir under suppressive cART potentiation by drugs of abuse$752,188
R01 · FY2016 · DA
The combinatorial effects of Opiates and the emerging promoter-variant strains of HIV-1 subtype C on HIV neuropathogensis and latency$744,839
R01 · FY2016 · DA
Role of HIV Env glycosylation in mucosal transmission$737,433
R01 · FY2016 · AI · contact PI
Transmitted/Founder SHIV macaque model$225,750
R21 · FY2016 · AI · contact PI
Role of HIV Env glycosylation in mucosal transmission$866,864
R01 · FY2015 · AI · contact PI
Transmitted/Founder SHIV macaque model$188,125
R21 · FY2015 · AI · contact PI
Transmitted/Founder SHIV macaque model$1
R21 · FY2015 · AI · contact PI
Role of HIV Env glycosylation in mucosal transmission$889,094
R01 · FY2014 · AI · contact PI
Escape From Broadly Neutralizing MAbs by Genetically-Linked Early & Late HIV Envs$220,000
R21 · FY2013 · AI · contact PI